MA-X-CHEM
25.10.2021 20:02:07 CEST | Business Wire | Press release
X-Chem , the pioneer of DNA-encoded library (DEL) technology and recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of ComInnex , a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery.
With demand for high-quality discovery services increasing across the world, this complementary pairing of a North American leader in DEL and medicinal chemistry with a European leader in synthetic chemistry and custom DEL services delivers the capacity, footprint and expertise to better serve the demands of customers in a global market.
“As a united company, with an increased global presence, we are positioned to meet the increasing demand for innovative chemistry solutions and high-quality discovery services worldwide,” noted Matt Clark , Ph.D., CEO of X-Chem. “The acquisition of ComInnex further extends X-Chem’s expertise and scale of DEL services to help biopharma clients of any size efficiently unlock exponential possibilities in small molecule drug discovery.”
“Combining X-Chem, the world leader and pioneer of high-quality DEL technology, and ComInnex, a leader in the most important trends and novel approaches in early-stage drug discovery chemistry, will yield a powerhouse partner for innovative drug discovery solutions,” commented Alex Drijver , CEO of ComInnex.
ComInnex’s technology expertise in flow chemistry, photochemistry and software development will expand X-Chem’s capabilities supporting the creation and delivery of innovative services for drug developers on a global scale.
About X-Chem
X-Chem, Inc. is the leader in small molecule discovery science, providing pharmaceutical and biotech companies a complete, seamless solution for screening, hit validation and lead optimization. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. X-Chem empowers partners to rapidly screen billions of diverse, drug-like compounds simultaneously and easily identify potent hits that exhibit desired selectivity and mode of action with attractive physicochemical properties. In-house, lead optimization services enable clients to progress their compounds directly for even higher quality outputs. Our expertise in medicinal chemistry, custom synthesis and scale-up process chemistry enables us to support all aspects of drug discovery, supporting lead optimization through candidate identification.
About ComInnex
ComInnex is a synthetic chemistry group passionate about small molecule design and synthesis. Based in Budapest, Hungary, ComInnex supports early-stage drug discovery through a range of products and services, focusing on the latest technologies and adapting to new and emerging trends. The ComInnex platform and toolkit enables rapid design and validation of novel E3 ligase ligands and linkers for targeted protein degradation to accelerate research projects in this area.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005075/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna Backs Google’s Universal Commerce Protocol (UCP) to Enable Agentic Commerce Across Platforms2.2.2026 14:30:00 CET | Press release
Klarna, the global digital bank and flexible payments provider, is joining Google's Universal Commerce Protocol (UCP), an open standard designed to help AI agents and commerce systems work together across the full shopping lifecycle, from discovery and purchase through post-purchase support. UCP enables consumers to shop seamlessly in AI conversations while giving agents, merchant systems, and payment providers a standardized way to interact across multiple AI platforms. The announcement builds on Klarna’s recent support for Google’s Agent Payments Protocol (AP2) and expands Klarna's multiyear partnership with Google across Google Pay, Google Store, Google Play, and Google Cloud infrastructure. Together, these efforts reflect ongoing collaboration to support open standards as AI increasingly shapes how consumers shop online. “As AI-driven shopping continues to evolve, it’s important that the underlying commerce infrastructure is built on openness, trust, and transparency,” said David S
Tastepoint by IFF Predicts Ten Flavor Trends for 20262.2.2026 14:15:00 CET | Press release
From cherry to chai spice, Tastepoint’s trend experts reveal ten flavors poised to stand out this year. Tastepoint by IFF (NYSE: IFF), a leader in innovative flavor creations and taste solutions, has identified ten flavors expected to shape the North American food and beverage landscape in 2026. These predictions spotlight flavors anticipated to trend in retail, food service and beyond throughout the coming year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202440399/en/ Flavors featured in Tastepoint by IFF's 2026 trend list. “To continue delivering product development solutions that meet consumers’ unique and changing needs, we stay attuned to industry and market trends, keeping a pulse on what’s relevant now and in the future,” said Nicole Potash, Tastepoint general manager. “Our annual flavor trend predictions reflect a vibrant mix of influences, from nostalgia-driven classics to global favorites gaining momentum in
AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need2.2.2026 13:30:00 CET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced that it has entered into a Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to develop a novel peptide-based Lead-212 (212Pb) radiotherapeutic with an initial focus on a gastrointestinal cancer with significant medical need, reflecting AdvanCell’s strategy to build a durable pipeline of differentiated targeted alpha therapies addressing large oncology markets. The collaboration brings together 48Hour Discovery’s peptide discovery platform and AdvanCell’s 212Pb expertise to rapidly construct and advance a peptide-based radiotherapeutic program. Leveraging AdvanCell’s scalable 212Pb platform, which integrates secure isotope supply and modular manufacturing with deep expertise in developing 212Pb radioligand therapies, the program is designed to enable a rapid, repeatable path into the clinic and support the expansion of AdvanCell’s target
Umm Al Qura for Development & Construction Company Launches Unified Digital Platform for Developers in Masar Destination2.2.2026 12:34:00 CET | Press release
During its participation in the Future Real Estate Forum 2026 Umm Al Qura for Development & Construction Company, the owner, developer, and operator of Masar Destination, announced the launch of a unified digital platform for property ownership within the destination through approved developers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202971654/en/ Future Semi Arial view of Masar (Photo: AETOSWire) The new digital platform provides accurate and up-to-date information in both Arabic and English about all approved developers within Masar destination, thus enhancing transparency and establishing high levels of regulation within an integrated urban system. This initiative, which reflects the Company’s responsible approach to urban development and its commitment to preserving the unique character of place and enhancing quality of life, was launched as part of the company’s participation in Future Real Estate Forum 2026,
BRUNO to Showcase Acclaimed Lifestyle and Travel Collections at Ambiente 20262.2.2026 09:00:00 CET | Press release
Tokyo-based lifestyle company BRUNO, Inc. (Headquarters: Shinjuku-ku, Tokyo; President & CEO: Tetsu Shiota), dedicated to the planning, development, and sale of lifestyle products, is pleased to announce its participation in Ambiente—the world’s leading international consumer goods trade fair held in Frankfurt, Germany. The company will showcase its two flagship brands: "BRUNO," a lifestyle brand dedicated to "enjoying life to the fullest," and "MILESTO," a premium travel brand designed for those who "live every day like a journey." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202663769/en/ Our participation in Ambiente marks a pivotal step in our global expansion strategy, as outlined in our current medium-term management plan. We are excited to introduce BRUNO and MILESTO—brands that have earned immense loyalty in Japan—to a global audience. Our exhibit showcases a curated selection of flagship products and latest inn
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom